flow trial semaglutide ppt 🔴Cardiovascular outcomes with by severity of chronic kidney disease in type 2 diabetes: the trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants 📊 New findings from the

Description

GLP-1 is an incretin hormone that stimulates insulin secretion in a glucose-dependent manner, reducing hypoglycaemia risk The hormone slows gastric emptying and suppresses appetite through receptors in the pancreas, brain, and gastrointestinal tract GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) are MHRA-approved for type 2 diabetes and weight management Common side effects include nausea, vomiting, and diarrhoea due to delayed gastric emptying and altered gut motility Patients should seek urgent medical attention for severe abdominal pain with persistent vomiting, as this may indicate pancreatitis GLP-1 medications do not directly impair digestive enzyme production, and routine enzyme supplementation is not clinically indicated Table of Contents What Does GLP-1 Stand For

Psoriasis Advise patients that cases of new-onset psoriasis have been reported with the use of DUPIXENT

The frustration of stalled progress feels acute after experiencing steady loss

This document may contain links to third-party websites

Weight loss itself can improve mood and self-esteem in some patients, while the stress of lifestyle change or social judgment around medication use can worsen mental health in others